Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to […]
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University. […]
In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]
Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases […]
To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]
Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]
Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]
The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]